The versatile functionality of the complement system has gained increasing interest in the context of PD-L1/PD-1 signaling, especially in the field of cancer research, where therapy non-responding to PD-L1/PD-1-targeting agents poses an ongoing challenge, despite resounding treatment success in many solid tumor entities particularly of advanced stages (23). Here, CD274 is linked to cancer.